Elanco Animal Health (ELAN) Leerink Global Healthcare Conference 2026 summary

Financial performance and outlook

• Ended Q4 with strong results, exceeding guidance on revenue, earnings, EPS, and cash flow, driven by innovation revenue of $892 million, above expectations.

• Raised 2026 innovation revenue expectations to $1.15 billion, maintaining mid-single-digit top-line growth, high single-digit EBITDA growth, and low double-digit EPS growth targets.

• Leverage expected to reach low 3s in 2026 and below 3 in 2027, providing flexibility for shareholder returns.

• Achieved market share growth in every major category in 2025, with notable gains in vaccines, parasiticides, Rx, OTC, OA, pain, and dermatology.

• Farm business grew 17% in Q4, led by Experior, with favorable macro trends supporting continued growth.

Product innovation and market strategy

• Credelio Quattro's growth driven by expanding clinic penetration and market share, with 35% of volume from new starts, supported by direct-to-consumer campaigns and product differentiation.

• Zenrelia saw strong momentum post-label update, now in over half of U.S. clinics, with ongoing efforts to further update the label and expand market share.

• Befrena launch planned in two stages, with high anticipated adoption and a comprehensive dermatology portfolio expected to accelerate ramp rate.

• Portfolio effect from new products is driving growth across the business, with a halo effect benefiting other product lines.

• Future innovation pipeline includes five to six potential blockbusters by 2031, focusing on large markets like derm and parasiticides, with additional investment in mAbs and immunotherapy.

Operational efficiency and capital allocation

• Elanco Ascend program targets $200–$250 million EBIT improvement by 2028, leveraging AI, automation, and restructuring for cost savings.

• $25 million in savings expected in 2026 from restructuring, with full $60 million run rate benefit in 2027.

• Gross margin improvement of 40 basis points guided for 2026, with 200–350 basis points of EBITDA margin enhancement expected by 2028.

• Capital deployment priorities remain organic investment and debt reduction, with leverage targeted below 3x in 2027 and potential for shareholder returns thereafter.

• Tuck-under M&A will focus on R&D capabilities or products that leverage existing distribution, with strict financial discipline to ensure accretive growth.